Pictet Asset Management’s Marvell Technology MRVL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$519M Sell
1,742,336
-2,364,321
-58% -$474M 0.5% 40
2026
Q1
$407M Buy
4,106,657
+554,801
+16% +$46.6M 0.43% 47
2025
Q4
$302M Sell
3,551,856
-44,792
-1% -$3.92M 0.29% 80
2025
Q3
$302M Sell
3,596,648
-3,130,184
-47% -$230M 0.29% 85
2025
Q2
$521M Sell
6,726,832
-1,049,364
-13% -$65.5M 0.53% 38
2025
Q1
$479M Buy
7,776,196
+488,610
+7% +$47.4M 0.53% 40
2024
Q4
$805M Sell
7,287,586
-2,383,082
-25% -$221M 0.87% 20
2024
Q3
$697M Sell
9,670,668
-1,089,781
-10% -$75.3M 0.77% 25
2024
Q2
$752M Buy
10,760,449
+144,648
+1% +$10.1M 0.86% 23
2024
Q1
$753M Sell
10,615,801
-2,312,328
-18% -$158M 0.82% 25
2023
Q4
$780M Buy
12,928,129
+2,381,056
+23% +$129M 0.86% 26
2023
Q3
$571M Buy
+10,547,073
New +$623M 0.7% 31

Other funds holding MRVL

Pictet Asset Management's MRVL Position: Q2 2026 in Review

Pictet Asset Management reduced its Marvell Technology (MRVL) stake by 58% in Q2 2026, selling an estimated $474M and leaving 1,742,336 shares worth $519M. The position accounts for 0.5% of the portfolio, ranked #40.

Pictet Asset Management first reported a position in MRVL in Q3 2023 and has held it in 12 quarters since. The position peaked at $805M in Q4 2024. 2,202 funds tracked by Wall St. Rank hold MRVL as of Q2 2026.

  • Pictet Asset Management held 1,742,336 shares of Marvell Technology worth $519M as of Q2 2026.
  • Pictet Asset Management sold 2,364,321 Marvell Technology shares in Q2 2026, an estimated $474M.
  • Marvell Technology made up 0.5% of Pictet Asset Management's portfolio in Q2 2026, its #40 holding.
  • Pictet Asset Management first reported a position in Marvell Technology in Q3 2023 and has held it in 12 quarters since.
  • Pictet Asset Management's Marvell Technology position peaked at $805M in Q4 2024.
  • 2,202 funds tracked by Wall St. Rank held Marvell Technology as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.